Matches in SemOpenAlex for { <https://semopenalex.org/work/W2967110635> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W2967110635 abstract "Abstract INTRODUCTION: To determine the recommended Phase II dose of RRx-001, a radiosensitizer with vascular normalizing properties, when used with whole-brain radiation therapy (WBRT) for brain metastases, and to assess whether quantitative changes in perfusion MRI after RRx-001 correlate with response. METHODS AND MATERIALS: Five centers participated in this phase I/II trial of RRx-001 given once pre-WBRT then twice weekly during WBRT (30 Gy/10 fractions). Four dose levels were planned (5 mg/m2, 8.4 mg/m2, 16.5 mg/m2, 27.5 mg/m2). Dose-escalation was managed by the Time-to-Event Continual Reassessment Model (TITE-CRM). Correlative DCE-MRI was performed in a subset of patients and linear mixed models used to correlate change in 24-hour T1, Ktrans (capillary permeability) and Vp (plasma volume) with change in tumor volume. RESULTS: Between 2015–2017, 31 patients were enrolled. Two patients dropped out prior to any therapy and 7 were treated with concurrent temozolomide following a study amendment. Median age was 60 years (range, 30–76) and 17 were male. The most common tumor types were melanoma (58%) and non-small cell lung cancer (20%). No dose-limiting toxicities were observed. The most common severe adverse event was grade 3 asthenia in 6.9% (2/29). The median intracranial response rate was 46% (95%CI 24–68) and median overall survival was 5.2 months (95%CI 4.5–9.4). No neurologic deaths occurred. Among 10 evaluable patients undergoing DCE-MRI, a reduction in Vp 24 hours after RRx-001 was associated with reduced tumor volume at 1 month and 4 months (p≤0.01). CONCLUSION: The addition of RRx-001 to WBRT is safe and well-tolerated with favorable intracranial response rates. Because activity was observed across all dose levels, and in the absence of a dose response, the recommended Phase 2 dose is 10 mg administered twice weekly. A reduction in Vp by DCE-MRI 24 hours after RRx-001 suggests anti-angiogenic activity that is associated with longer-term tumor response." @default.
- W2967110635 created "2019-08-22" @default.
- W2967110635 creator A5004681706 @default.
- W2967110635 creator A5014527725 @default.
- W2967110635 creator A5020712237 @default.
- W2967110635 creator A5021609838 @default.
- W2967110635 creator A5031640214 @default.
- W2967110635 creator A5034370633 @default.
- W2967110635 creator A5046132413 @default.
- W2967110635 creator A5050339404 @default.
- W2967110635 creator A5052914934 @default.
- W2967110635 creator A5053441903 @default.
- W2967110635 creator A5060316016 @default.
- W2967110635 creator A5060495866 @default.
- W2967110635 creator A5061660342 @default.
- W2967110635 creator A5063863193 @default.
- W2967110635 creator A5066404810 @default.
- W2967110635 creator A5067646281 @default.
- W2967110635 creator A5068090040 @default.
- W2967110635 creator A5070141227 @default.
- W2967110635 creator A5070289110 @default.
- W2967110635 creator A5076238068 @default.
- W2967110635 date "2019-08-01" @default.
- W2967110635 modified "2023-10-17" @default.
- W2967110635 title "TRLS-07. BRAINSTORM: OUTCOMES FROM A MULTI-INSTITUTIONAL PHASE I/II STUDY OF RRx-001 IN COMBINATION WITH WHOLE BRAIN RADIATION THERAPY FOR PATIENTS WITH BRAIN METASTASES" @default.
- W2967110635 doi "https://doi.org/10.1093/noajnl/vdz014.040" @default.
- W2967110635 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7213090" @default.
- W2967110635 hasPublicationYear "2019" @default.
- W2967110635 type Work @default.
- W2967110635 sameAs 2967110635 @default.
- W2967110635 citedByCount "0" @default.
- W2967110635 crossrefType "journal-article" @default.
- W2967110635 hasAuthorship W2967110635A5004681706 @default.
- W2967110635 hasAuthorship W2967110635A5014527725 @default.
- W2967110635 hasAuthorship W2967110635A5020712237 @default.
- W2967110635 hasAuthorship W2967110635A5021609838 @default.
- W2967110635 hasAuthorship W2967110635A5031640214 @default.
- W2967110635 hasAuthorship W2967110635A5034370633 @default.
- W2967110635 hasAuthorship W2967110635A5046132413 @default.
- W2967110635 hasAuthorship W2967110635A5050339404 @default.
- W2967110635 hasAuthorship W2967110635A5052914934 @default.
- W2967110635 hasAuthorship W2967110635A5053441903 @default.
- W2967110635 hasAuthorship W2967110635A5060316016 @default.
- W2967110635 hasAuthorship W2967110635A5060495866 @default.
- W2967110635 hasAuthorship W2967110635A5061660342 @default.
- W2967110635 hasAuthorship W2967110635A5063863193 @default.
- W2967110635 hasAuthorship W2967110635A5066404810 @default.
- W2967110635 hasAuthorship W2967110635A5067646281 @default.
- W2967110635 hasAuthorship W2967110635A5068090040 @default.
- W2967110635 hasAuthorship W2967110635A5070141227 @default.
- W2967110635 hasAuthorship W2967110635A5070289110 @default.
- W2967110635 hasAuthorship W2967110635A5076238068 @default.
- W2967110635 hasBestOaLocation W29671106351 @default.
- W2967110635 hasConcept C126322002 @default.
- W2967110635 hasConcept C143998085 @default.
- W2967110635 hasConcept C197934379 @default.
- W2967110635 hasConcept C2776256026 @default.
- W2967110635 hasConcept C2777389519 @default.
- W2967110635 hasConcept C2989005 @default.
- W2967110635 hasConcept C509974204 @default.
- W2967110635 hasConcept C71924100 @default.
- W2967110635 hasConceptScore W2967110635C126322002 @default.
- W2967110635 hasConceptScore W2967110635C143998085 @default.
- W2967110635 hasConceptScore W2967110635C197934379 @default.
- W2967110635 hasConceptScore W2967110635C2776256026 @default.
- W2967110635 hasConceptScore W2967110635C2777389519 @default.
- W2967110635 hasConceptScore W2967110635C2989005 @default.
- W2967110635 hasConceptScore W2967110635C509974204 @default.
- W2967110635 hasConceptScore W2967110635C71924100 @default.
- W2967110635 hasLocation W29671106351 @default.
- W2967110635 hasLocation W29671106352 @default.
- W2967110635 hasOpenAccess W2967110635 @default.
- W2967110635 hasPrimaryLocation W29671106351 @default.
- W2967110635 hasRelatedWork W10226643 @default.
- W2967110635 hasRelatedWork W10949566 @default.
- W2967110635 hasRelatedWork W13573813 @default.
- W2967110635 hasRelatedWork W3551421 @default.
- W2967110635 hasRelatedWork W4527439 @default.
- W2967110635 hasRelatedWork W4763142 @default.
- W2967110635 hasRelatedWork W5806089 @default.
- W2967110635 hasRelatedWork W8255009 @default.
- W2967110635 hasRelatedWork W8512914 @default.
- W2967110635 hasRelatedWork W8744549 @default.
- W2967110635 isParatext "false" @default.
- W2967110635 isRetracted "false" @default.
- W2967110635 magId "2967110635" @default.
- W2967110635 workType "article" @default.